3. Special items

The consolidated statements of income for the years 2010 and 2009 include several special items relating to the acquisition of APP Pharmaceuticals, Inc. in 2008. The tables below reconcile adjusted earnings to earnings according to U.S. GAAP.

€ in millions Other financial result Net income attributable to Fresenius SE & Co. KGaA
Earnings 2010, adjusted   660
Mandatory Exchangeable Bonds (mark-to-market) -98 -70
Contingent Value Rights (mark-to-market) 32 32
Earnings 2010 according to U.S. GAAP   622

€ in millions Other financial result Net income attributable to Fresenius SE & Co. KGaA
Earnings 2010, adjusted   660
Mandatory Exchangeable Bonds (mark-to-market) -98 -70
Contingent Value Rights (mark-to-market) 32 32
Earnings 2010 according to U.S. GAAP   622

€ in millions Other financial result Net income attributable to Fresenius SE & Co. KGaA
Earnings 2009, adjusted   514
Mandatory Exchangeable Bonds (mark-to-market) -37 -26
Contingent Value Rights (mark-to-market) 6 6
Earnings 2009 according to U.S. GAAP   494

€ in millions Other financial result Net income attributable to Fresenius SE & Co. KGaA
Earnings 2009, adjusted   514
Mandatory Exchangeable Bonds (mark-to-market) -37 -26
Contingent Value Rights (mark-to-market) 6 6
Earnings 2009 according to U.S. GAAP   494

For further information regarding Mandatory Exchangeable Bonds and Contingent Value Rights see note 10, Other financial result.

Continue reading:
4. Sales

QUICKFINDER

History

Tools

My Annual Report

Your page has been added successfully

Link für Popup